The Most Effective Weight Loss Supplement - Rimonabant Powder (AASraw)
http://www.aasraw.com/products/rimonabant-powder/ - Rimonabant is an anorectic anti-obesity drug and Rimonabant powder is the raw material for many weight loss supplement, such as Rimonabant are Zimulti, Acomplia, Monaslim, Bethin, Riobant, Remonabent, Rimoslim and Riomont in the market.Rimonabant powder can help you to loss weight effectively.
http://www.aasraw.com/products/rimonabant-powder/ - Rimonabant is an anorectic anti-obesity drug and Rimonabant powder is the raw material for many weight loss supplement, such as Rimonabant are Zimulti, Acomplia, Monaslim, Bethin, Riobant, Remonabent, Rimoslim and Riomont in the market.Rimonabant powder can help you to loss weight effectively.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Email: aas11@aasraw.com Whatsapp:+8618928439036<br />
with a BMI greater than 30 or people whose BMI was greater than 27 but who<br />
had other risk factors like dyslipidemia and type 2-diabetes.<br />
In June 2006, European Commission approved its sale and it was submitted<br />
to FDA for US approval. However, FDA’s EMDAC voted against the drug,<br />
concluding that Sanofi-Aventis, the manufacturers of <strong>Rimonabant</strong>, had not<br />
demonstrated its safety effectively. In 2009, EMEA withdrew Acomplia, after<br />
suspending it in 2008, because of severe psychological side effects of the drug,<br />
such as suicidal tendencies. FDA never approved <strong>Rimonabant</strong> and therefore, it<br />
has never been marketed in the US.<br />
2. <strong>Rimonabant</strong><br />
<strong>Rimonabant</strong> is an anorectic anti-obesity drug produced and marketed by<br />
Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its<br />
main avenue of effect is reduction in appetite. <strong>Rimonabant</strong> is the first selective<br />
CB1 receptor blocker to be approved for use anywhere in the world.<br />
<strong>Rimonabant</strong> is approved in 38 countries including the E.U., Mexico, and<br />
Brazil. It was rejected for approval for use in the United States. This decision<br />
was made after a U.S. advisory panel recommended the medicine not be<br />
approved because it may increase suicidal thinking and depression.<br />
2
Change language